Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR inhib...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2020-05-01
Saila:Molecular Cancer
Gaiak:
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
Sarrera elektronikoa:http://link.springer.com/article/10.1186/s12943-020-01202-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak